|
1
|
Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu
YP, Yu XJ, Zhang XD, Ming PH, Zhou GB and Huang L: The natural
compound magnolol inhibits invasion and exhibits potential in human
breast cancer therapy. Sci Rep. 3:30982013.PubMed/NCBI
|
|
2
|
Charpentier M and Martin S: Interplay of
stem cell characteristics, EMT, and microtentacles in circulating
breast tumor cells. Cancers (Basel). 5:1545–1565. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chambers AF and Matrisian LM: Changing
views of the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Peschos D, Damala C, Stefanou D, Tsanou E,
Assimakopoulos D, Vougiouklakis T, Charalabopoulos K and Agnantis
NJ: Expression of matrix metalloproteinase-9 (gelatinase B) in
benign, premalignant and malignant laryngeal lesions. Histol
Histopathol. 21:603–608. 2006.PubMed/NCBI
|
|
5
|
Chang SH, Kanasaki K, Gocheva V, et al:
VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine
protease inhibitor balance in venules, causing basement membrane
degradation and mother vessel formation. Cancer Res. 69:4537–4544.
2009. View Article : Google Scholar
|
|
6
|
Quaranta M, Daniele A, Coviello M, et al:
MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res.
27:3593–3600. 2007.
|
|
7
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Belugali Nataraj N and Salimath BP:
Crosstalk between VEGF and novel angiogenic protein regulates tumor
angiogenesis and contributes to aggressiveness of breast carcinoma.
Cell Signal. 25:277–294. 2013.PubMed/NCBI
|
|
9
|
Stathopoulos J, Armakolas A, Stathopoulos
GP and Gomatos IP: Plasma VEGF levels in breast cancer patients
with and without metastases. Oncol Lett. 1:739–741. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Recchia F, Candeloro G, Necozione S, et
al: Vascular endothelial growth factor expression and T-regulatory
cells in premenopausal breast cancer. Oncol Lett. 5:1117–1122.
2013.PubMed/NCBI
|
|
11
|
Liu D, Guo H, Li Y, et al: Association
between polymorphisms in the promoter regions of matrix
metalloproteinases (MMPs) and risk of cancer metastasis: a
meta-analysis. PLoS One. 7:e312512012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Radisky ES and Radisky DC: Matrix
metalloproteinase-induced epithelial-mesenchymal transition in
breast cancer. J Mammary Gland Biol Neoplasia. 15:201–212. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lohela M, Bry M, Tammela T and Alitalo K:
VEGFs and receptors involved in angiogenesis versus
lymphangiogenesis. Curr Opin Cell Biol. 21:154–165. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ranuncolo SM, Armanasco E, Cresta C, et
al: Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up
and in the assessment of prognosis in breast cancer patients. Int J
Cancer. 106:745–751. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hao L, Zhang C, Qiu Y, et al:
Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node
metastasis in human breast cancer. Cancer Lett. 253:34–42. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pellikainen JM, Ropponen KM, Kataja VV, et
al: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in
breast cancer with a special reference to activator protein-2,
HER2, and prognosis. Clin Cancer Res. 10:7621–7628. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldhirsch A, Glick JH, Gelber RD, et al:
Meeting highlights: international expert consensus on the primary
therapy of early breast cancer 2005. Ann Oncol. 16:1569–1583. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rakha EA, El-Sayed ME, Green AR, et al:
Prognostic markers in triple-negative breast cancer. Cancer.
109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Turner N, Tutt A and Ashworth A: Hallmarks
of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819.
2004.
|
|
20
|
Riedel F, Götte K, Bergler W and Hörmann
K: Inverse correlation of apoptotic and angiogenic markers in
squamous cell carcinoma of the head and neck. Oncol Rep. 8:471–476.
2001.PubMed/NCBI
|
|
21
|
Riedel F, Götte K, Schwalb J, et al:
Expression of 92-kDa type IV collagenase correlates with angiogenic
markers and poor survival in head and neck squamous cell carcinoma.
Int J Oncol. 17:1099–1105. 2000.PubMed/NCBI
|
|
22
|
Zucker S, Mirza H, Conner CE, et al:
Vascular endothelial growth factor induces tissue factor and matrix
metalloproteinase production in endothelial cells: conversion of
prothrombin to thrombin results in progelatinase A activation and
cell proliferation. Int J Cancer. 75:780–786. 1998. View Article : Google Scholar
|
|
23
|
Hawinkels LJ, Zuidwijk K, Verspaget HW, et
al: VEGF release by MMP-9 mediated heparan sulphate cleavage
induces colorectal cancer angiogenesis. Eur J Cancer. 44:1904–1913.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang L, Ma X, Tian Q, et al: Inhibition of
angiogenesis and invasion by DMBT is mediated by downregulation of
VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer
cells. Food Chem Toxicol. 56:204–213. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Elshal MF and McCoy JP: Multiplex bead
array assays: performance evaluation and comparison of sensitivity
to ELISA. Methods. 38:317–323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sylvester JE and Kron SJ: A bead-based
activity screen for small-molecule inhibitors of signal
transduction in chronic myelogenous leukemia cells. Mol Cancer
Ther. 9:1469–1481. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reeves KW, Ness RB, Stone RA, et al:
Vascular endothelial growth factor and breast cancer risk. Cancer
Causes Control. 20:375–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
